Cabrera-Navarro P
Servicio de Neumología, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, España.
Arch Bronconeumol. 2006 May;42(5):241-5. doi: 10.1016/s1579-2129(06)60453-9.
Omalizumab is a monoclonal antibody that interrupts allergic reaction--irrespective of the nature of the allergen--by blocking free immunoglobulin E (IgE). The IgE is thus prevented from attaching to cell receptors and setting in motion an allergic cascade of inflammatory mediators. Other interesting biological effects of omalizumab are that it downregulates IgE receptor expression on cell membranes and reduces bronchial eosinophilic infiltration. Clinical trials have demonstrated omalizumab's efficacy and safety in treating most allergic disorders. However, given its high cost, omalizumab is generally reserved for more severe cases of asthma and for asthma that responds poorly to conventional treatments.
奥马珠单抗是一种单克隆抗体，它通过阻断游离免疫球蛋白E（IgE）来中断过敏反应——无论过敏原的性质如何。这样就可以防止IgE附着在细胞受体上，并引发一系列过敏炎症介质的连锁反应。奥马珠单抗的其他有趣生物学效应包括下调细胞膜上IgE受体的表达以及减少支气管嗜酸性粒细胞浸润。临床试验已证明奥马珠单抗在治疗大多数过敏性疾病方面的有效性和安全性。然而，鉴于其成本高昂，奥马珠单抗通常仅用于更严重的哮喘病例以及对传统治疗反应不佳的哮喘。
